Treating the anemic oncology patient with intravenous iron: Why, when, and how?

摘要: AB S TRA C T Anemia is common in oncology patients and associated with poor outcomes reduced quality of life. can be treated blood transfusions and/or erythropoietin-stimulating agents (ESAs) combination iron. ESAs have been widely used by nephrologists for the management anemia chronic kidney disease (CKD). Iron supplementation has shown to improve hemoglobin response ESAs, reduce ESA requirement, life CKD cancer. Despite these findings, intravenous iron underutilized cancer patients. This review will discuss role patients, as well discussing methods administration including use total-dose infusion regimens. Studies that administered a equal safety efficacy multiple low-dose infusions. Total-dose may thereby patient convenience hospital costs administering IV